Association of hOGG1-Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer

doi:10.1111/1759-7714.13799

CNU IR > College of Sustainable Environment and Recreation > Dept. of Sports Management > Periodical Articles > Item 310902800/34080

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34080

Title:	Association of hOGG1-Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer
Authors:	Chen, Ming-Jenn Shen, Ching-Ju Wang, Lee Chen, Po-Ming Chen, Chih-Yi Lee, Huei
Contributors:	Chi Mei Med Ctr, Dept Surg Chia Nan Univ Pharm & Sci, Coll Leisure & Recat Management, Dept Sports Management Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Dept Gynecol & Obstet Chung Shan Med Univ, Dept Publ Heath Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery Chung Shan Med Univ Hosp, Dept Surg
Keywords:	Deletion mutation hOGG1 Ser326Cys polymorphism non8208 small cell lung cancer (NSCLC)
Date:	2021
Issue Date:	2022-11-18 11:23:06 (UTC+8)
Publisher:	Wiley
Abstract:	Background The human 8-oxoguanine DNA glycosylase 1 (hOGG1) gene encodes a DNA glycosylase that removes 8-hydroxy-2-deoxyguanine (8-OH-dG) DNA damage to protect against gene mutations. The association of hOGG1 Ser326Cys polymorphism with lung cancer risk has predicted that hOGG1-Cys variants are less effective at removing 8-OH-dG damage from DNA; therefore, these variants might show an increased occurrence of tumor suppressor gene and oncogene mutations. However, no evidence has yet supported this hypothesis. Methods Direct sequencing was performed to examine the mutations of p53 and EGFR genes in lung tumors from patients with non-small cell lung cancer (NSCLC). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to examine hOGG1 Ser326Cys polymorphism in this study population. Results A total of 99 p53-mutated and 99 EGFR-mutated patients with NSCLC were selected to explore the possible associations of these mutations with hOGG1 Ser326Cys polymorphism. The p53-mutated and EGFR-mutated patients were divided into nondeletion and deletion subgroups. P53 deletion mutations were more commonly observed in male than in female patients (P = 0.030). However, EGFR exon 19 deletion mutations were more prevalent in female and adenocarcinoma patients than in male and squamous cell carcinoma patients (P = 0.028 for genders, P = 0.017 for tumor histology). Interestingly, p53 and EGFR exon 19 deletion mutations were more frequent in patients with hOGG1 Ser/Cys + Cys/Cys hOGG1-Cys variants than with the hOGG1 Ser/Ser genotype (P = 0.010 for p53, P = 0.032 for EGFR). Conclusions We suggest that the association of hOGG1 Ser326Cys polymorphism with lung cancer risk could be partially explained by increases in p53 and EGFR deletion mutations. Key points Significant findings of the study NSCLC patients with hOGG1-Cys variants may have a higher risk of p53 and EGFR deletion mutations than with hOGG1 Ser/Ser genotype. What this study adds NSCLC patients with hOGG1-Cys variants might be helpful to predict patients having higher risk of EGFR exon 19 deletion mutations and these patients who were treated with gefitinib or erlotinib could be a higher risk to occur EGFR T790M mutation.
Relation:	Thoracic Cancer, v.12, n.4, pp.5
Appears in Collections:	[Dept. of Sports Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.11111759-7714.13799.pdf		129Kb	Adobe PDF	151	View/Open
index.html		0Kb	HTML	1002	View/Open

Loading...